Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-6: Eloralintide once weekly in adults with persistent obesity or overweight already receiving weekly incretin therapy
CTR20260956Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of eloralintide in obesity, Overweight, sponsored by Eli Lilly and Company. Started Mar 2026; status: active.
02
Drugs
eloralintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20260956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260956.